Review





Similar Products

95
R&D Systems antibodies against ucp1
Alterations in hepatic mitochondrial proteins during P. yoelii XNL infection. Pgc-1 α messenger RNA expression normalized to 18S rRNA (A), mitochondrial DNA copy number ( mtDNA CN ) (C) in liver samples, and their Pearson correlations with parasitemia (B, D) are shown. Representative immunoblots and corresponding densitometric analyses of <t>UCP1,</t> UCP2, and OPA1 in liver samples. Protein expression levels were normalized to GAPDH and are presented relative to day 0. Data represented from a single longitudinal study. Data represented as mean ± SEM. * P < 0.05 and ** P < 0.01. D, day.
Antibodies Against Ucp1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/Human%2FMouse+UCP1+Antibody/pmc13743347-121-23-27
Average 95 stars, based on 1 article reviews
antibodies against ucp1 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

97
Cell Signaling Technology Inc antibodies against runx2
Alterations in hepatic mitochondrial proteins during P. yoelii XNL infection. Pgc-1 α messenger RNA expression normalized to 18S rRNA (A), mitochondrial DNA copy number ( mtDNA CN ) (C) in liver samples, and their Pearson correlations with parasitemia (B, D) are shown. Representative immunoblots and corresponding densitometric analyses of <t>UCP1,</t> UCP2, and OPA1 in liver samples. Protein expression levels were normalized to GAPDH and are presented relative to day 0. Data represented from a single longitudinal study. Data represented as mean ± SEM. * P < 0.05 and ** P < 0.01. D, day.
Antibodies Against Runx2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/RUNX2+Rabbit+mAb/pm42988806-487-9-12
Average 97 stars, based on 1 article reviews
antibodies against runx2 - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

97
Cell Signaling Technology Inc antibody against iba 1
Alterations in hepatic mitochondrial proteins during P. yoelii XNL infection. Pgc-1 α messenger RNA expression normalized to 18S rRNA (A), mitochondrial DNA copy number ( mtDNA CN ) (C) in liver samples, and their Pearson correlations with parasitemia (B, D) are shown. Representative immunoblots and corresponding densitometric analyses of <t>UCP1,</t> UCP2, and OPA1 in liver samples. Protein expression levels were normalized to GAPDH and are presented relative to day 0. Data represented from a single longitudinal study. Data represented as mean ± SEM. * P < 0.05 and ** P < 0.01. D, day.
Antibody Against Iba 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/Iba1%2FAIF-1+XP+Rabbit+mAb/pm42986375-88-13-18
Average 97 stars, based on 1 article reviews
antibody against iba 1 - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

90
Novus Biologicals mouse mab against human sulf2
Alterations in hepatic mitochondrial proteins during P. yoelii XNL infection. Pgc-1 α messenger RNA expression normalized to 18S rRNA (A), mitochondrial DNA copy number ( mtDNA CN ) (C) in liver samples, and their Pearson correlations with parasitemia (B, D) are shown. Representative immunoblots and corresponding densitometric analyses of <t>UCP1,</t> UCP2, and OPA1 in liver samples. Protein expression levels were normalized to GAPDH and are presented relative to day 0. Data represented from a single longitudinal study. Data represented as mean ± SEM. * P < 0.05 and ** P < 0.01. D, day.
Mouse Mab Against Human Sulf2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/Sulfatase-2%2FSULF2+Antibody+(2B4)+-+BSA+Free/pm42975691-45-37-43
Average 90 stars, based on 1 article reviews
mouse mab against human sulf2 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
Novus Biologicals antibodies against col i
Alterations in hepatic mitochondrial proteins during P. yoelii XNL infection. Pgc-1 α messenger RNA expression normalized to 18S rRNA (A), mitochondrial DNA copy number ( mtDNA CN ) (C) in liver samples, and their Pearson correlations with parasitemia (B, D) are shown. Representative immunoblots and corresponding densitometric analyses of <t>UCP1,</t> UCP2, and OPA1 in liver samples. Protein expression levels were normalized to GAPDH and are presented relative to day 0. Data represented from a single longitudinal study. Data represented as mean ± SEM. * P < 0.05 and ** P < 0.01. D, day.
Antibodies Against Col I, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/Collagen+I+alpha+1+Antibody+(COL-1)/10__3390_slash_biomedicines14112534-98-11-15
Average 95 stars, based on 1 article reviews
antibodies against col i - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Miltenyi Biotec antibodies against human cd45
a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of <t>human</t> <t>CD45-positive</t> (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.
Antibodies Against Human Cd45, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/CD45+Antibody%2C+anti-human%2C+REAfinity/bio_rxiv__64898__2026__11__02__763650-299-18-22
Average 96 stars, based on 1 article reviews
antibodies against human cd45 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

86
Servicebio Inc antibodies against tnf α
In vivo immunomodulatory effects of different modified surfaces in a DM model. (A) Schematic representation of the animal modeling and experimental treatment workflow. (B, C) hematoxylin and eosin staining of the peri-implant tissues in the femurs of DM rats 1 week after implantation, accompanied by quantitative analysis of the fibrous capsule thickness (scale bar = 100 μm, n = 5). (D–G) Immunofluorescence staining evaluating the polarization state of macrophages surrounding the implants (green: macrophage marker cluster of differentiation (CD) 68; red: M1 marker CD86 and M2 marker CD206; blue: nuclei), along with corresponding quantitative analysis of the fluorescence signals (scale bar = 100 μm, n = 5). (H–K) Immunohistochemical staining assessing the expression of the pro-inflammatory marker <t>tumor</t> <t>necrosis</t> <t>factor-α</t> and the anti-inflammatory marker interleukin-10 in the peri-implant area, with quantitative results of the positive staining areas (scale bar = 100 μm, n = 5). Data are expressed as the mean ± standard deviation, with statistical analysis performed using one-way ANOVA and Tukey's post-hoc test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate statistical significance.
Antibodies Against Tnf α, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/anti+occludin/pmc13273899-526-14-18
Average 86 stars, based on 1 article reviews
antibodies against tnf α - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

93
Boster Bio antibody against tnf
In vivo immunomodulatory effects of different modified surfaces in a DM model. (A) Schematic representation of the animal modeling and experimental treatment workflow. (B, C) hematoxylin and eosin staining of the peri-implant tissues in the femurs of DM rats 1 week after implantation, accompanied by quantitative analysis of the fibrous capsule thickness (scale bar = 100 μm, n = 5). (D–G) Immunofluorescence staining evaluating the polarization state of macrophages surrounding the implants (green: macrophage marker cluster of differentiation (CD) 68; red: M1 marker CD86 and M2 marker CD206; blue: nuclei), along with corresponding quantitative analysis of the fluorescence signals (scale bar = 100 μm, n = 5). (H–K) Immunohistochemical staining assessing the expression of the pro-inflammatory marker <t>tumor</t> <t>necrosis</t> <t>factor-α</t> and the anti-inflammatory marker interleukin-10 in the peri-implant area, with quantitative results of the positive staining areas (scale bar = 100 μm, n = 5). Data are expressed as the mean ± standard deviation, with statistical analysis performed using one-way ANOVA and Tukey's post-hoc test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate statistical significance.
Antibody Against Tnf, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/Anti-TNF+alpha+Antibody+Picoband/pm42967715-149-15-18
Average 93 stars, based on 1 article reviews
antibody against tnf - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Bioss antibodies against trim32
In vivo immunomodulatory effects of different modified surfaces in a DM model. (A) Schematic representation of the animal modeling and experimental treatment workflow. (B, C) hematoxylin and eosin staining of the peri-implant tissues in the femurs of DM rats 1 week after implantation, accompanied by quantitative analysis of the fibrous capsule thickness (scale bar = 100 μm, n = 5). (D–G) Immunofluorescence staining evaluating the polarization state of macrophages surrounding the implants (green: macrophage marker cluster of differentiation (CD) 68; red: M1 marker CD86 and M2 marker CD206; blue: nuclei), along with corresponding quantitative analysis of the fluorescence signals (scale bar = 100 μm, n = 5). (H–K) Immunohistochemical staining assessing the expression of the pro-inflammatory marker <t>tumor</t> <t>necrosis</t> <t>factor-α</t> and the anti-inflammatory marker interleukin-10 in the peri-implant area, with quantitative results of the positive staining areas (scale bar = 100 μm, n = 5). Data are expressed as the mean ± standard deviation, with statistical analysis performed using one-way ANOVA and Tukey's post-hoc test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate statistical significance.
Antibodies Against Trim32, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/TRIM32+BBS11+Polyclonal+Antibody/pm42949011-53-0-6
Average 94 stars, based on 1 article reviews
antibodies against trim32 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
Bioss primary antibodies against alpha smooth muscle actin
In vivo immunomodulatory effects of different modified surfaces in a DM model. (A) Schematic representation of the animal modeling and experimental treatment workflow. (B, C) hematoxylin and eosin staining of the peri-implant tissues in the femurs of DM rats 1 week after implantation, accompanied by quantitative analysis of the fibrous capsule thickness (scale bar = 100 μm, n = 5). (D–G) Immunofluorescence staining evaluating the polarization state of macrophages surrounding the implants (green: macrophage marker cluster of differentiation (CD) 68; red: M1 marker CD86 and M2 marker CD206; blue: nuclei), along with corresponding quantitative analysis of the fluorescence signals (scale bar = 100 μm, n = 5). (H–K) Immunohistochemical staining assessing the expression of the pro-inflammatory marker <t>tumor</t> <t>necrosis</t> <t>factor-α</t> and the anti-inflammatory marker interleukin-10 in the peri-implant area, with quantitative results of the positive staining areas (scale bar = 100 μm, n = 5). Data are expressed as the mean ± standard deviation, with statistical analysis performed using one-way ANOVA and Tukey's post-hoc test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate statistical significance.
Primary Antibodies Against Alpha Smooth Muscle Actin, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibodies+against/Pan-Actin+Polyclonal+Antibody/10__1016_slash_s1875___5364_ascii40_26_ascii41_61226___5-53-0-19
Average 95 stars, based on 1 article reviews
primary antibodies against alpha smooth muscle actin - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


Alterations in hepatic mitochondrial proteins during P. yoelii XNL infection. Pgc-1 α messenger RNA expression normalized to 18S rRNA (A), mitochondrial DNA copy number ( mtDNA CN ) (C) in liver samples, and their Pearson correlations with parasitemia (B, D) are shown. Representative immunoblots and corresponding densitometric analyses of UCP1, UCP2, and OPA1 in liver samples. Protein expression levels were normalized to GAPDH and are presented relative to day 0. Data represented from a single longitudinal study. Data represented as mean ± SEM. * P < 0.05 and ** P < 0.01. D, day.

Journal: ImmunoHorizons

Article Title: Temporal dynamics of host immunometabolic response to Plasmodium yoelii infection

doi: 10.1093/immhor/vlag059

Figure Lengend Snippet: Alterations in hepatic mitochondrial proteins during P. yoelii XNL infection. Pgc-1 α messenger RNA expression normalized to 18S rRNA (A), mitochondrial DNA copy number ( mtDNA CN ) (C) in liver samples, and their Pearson correlations with parasitemia (B, D) are shown. Representative immunoblots and corresponding densitometric analyses of UCP1, UCP2, and OPA1 in liver samples. Protein expression levels were normalized to GAPDH and are presented relative to day 0. Data represented from a single longitudinal study. Data represented as mean ± SEM. * P < 0.05 and ** P < 0.01. D, day.

Article Snippet: Membranes were blocked using LI-COR Intercept Blocking Buffer for 1 h at room temperature and then incubated overnight at 4 °C with primary antibodies against UCP1 (1:1,000) (R&D Systems; Cat. #MAB6158), UCP2 (1:1,250) (R&D Systems; Cat. #AF4739), OPA-1 (1:1,250) (Cell Signaling Technology; Cat. #80471), and GAPDH (1:1,250) (Cell Signaling Technology; Cat. #5174).

Techniques: Infection, RNA Expression, Western Blot, Expressing

Temporal dynamics of parasitemia and host systemic responses. Time-course analyses illustrate the dynamic changes in parasitemia alongside hematological parameters, systemic inflammatory responses, iron homeostasis, hepatic function, bile acid metabolism, oxidative stress, and mitochondrial regulation. Data are presented as multiline curve plots over time, with each parameter normalized to the percentage of its maximal response (0%-100%). Smoothed curves represent sigmoidal trend fitting. (A, B) Parasitemia (%), RBCs, Hb, HCT, MCV, MCH, and reticulocytes. (C) Parasitemia (%), serum Lcn2, SAA, and EPO. (D, E) Parasitemia (%), liver iron, Hamp , Slc40a1 , Tfrc , and RBC FPN. (F) Parasitemia (%), serum TBAs, cholesterol, and bilirubin. (G) Parasitemia (%) and hepatic bile acid regulatory genes Cyp7a1 , Cyp7b1 , and Abcc2 . (H) Parasitemia (%) and hepatic oxidative stress–related markers, including liver MDA, Hmox1 , and Hnf4α . (I, J) Parasitemia (%) and key regulators of mitochondrial function, including hepatic Pgc-1α , mitochondrial DNA copy number ( mtDNA CN ), UCP1, UCP2, and OPA1, in the liver samples.

Journal: ImmunoHorizons

Article Title: Temporal dynamics of host immunometabolic response to Plasmodium yoelii infection

doi: 10.1093/immhor/vlag059

Figure Lengend Snippet: Temporal dynamics of parasitemia and host systemic responses. Time-course analyses illustrate the dynamic changes in parasitemia alongside hematological parameters, systemic inflammatory responses, iron homeostasis, hepatic function, bile acid metabolism, oxidative stress, and mitochondrial regulation. Data are presented as multiline curve plots over time, with each parameter normalized to the percentage of its maximal response (0%-100%). Smoothed curves represent sigmoidal trend fitting. (A, B) Parasitemia (%), RBCs, Hb, HCT, MCV, MCH, and reticulocytes. (C) Parasitemia (%), serum Lcn2, SAA, and EPO. (D, E) Parasitemia (%), liver iron, Hamp , Slc40a1 , Tfrc , and RBC FPN. (F) Parasitemia (%), serum TBAs, cholesterol, and bilirubin. (G) Parasitemia (%) and hepatic bile acid regulatory genes Cyp7a1 , Cyp7b1 , and Abcc2 . (H) Parasitemia (%) and hepatic oxidative stress–related markers, including liver MDA, Hmox1 , and Hnf4α . (I, J) Parasitemia (%) and key regulators of mitochondrial function, including hepatic Pgc-1α , mitochondrial DNA copy number ( mtDNA CN ), UCP1, UCP2, and OPA1, in the liver samples.

Article Snippet: Membranes were blocked using LI-COR Intercept Blocking Buffer for 1 h at room temperature and then incubated overnight at 4 °C with primary antibodies against UCP1 (1:1,000) (R&D Systems; Cat. #MAB6158), UCP2 (1:1,250) (R&D Systems; Cat. #AF4739), OPA-1 (1:1,250) (Cell Signaling Technology; Cat. #80471), and GAPDH (1:1,250) (Cell Signaling Technology; Cat. #5174).

Techniques:

a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood during treatment with ASNase (25 IU/mouse every 8 days) for 5 weeks. Treatment was discontinued following sacrifice of the vehicle-treated mice, and the remaining mice were monitored until reaching the experimental endpoint. Each dot represents an individual mouse. b. Bodyweight of mice shown in , expressed as the percentage of baseline bodyweight. Dots represent group means; error bars indicate SEM.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques:

a. Relative viability of leukemic cells isolated from mice treated with a single intravenous dose of ASNase (100 IU/mouse) or vehicle (n = 3 mice per group). Cells were treated ex vivo with a two-fold serial dilution of ASNase (maximum concentration 2000 mIU/mL) for 72 h before viability was assessed using CellTiter-Glo. Concentrations were log-transformed. Each dot represents the mean of three biological replicates; error bars indicate SD. b. Relative ASNS mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. **p = 0.0038 (unpaired two-tailed t-test). c. Relative ATF4 mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. *p = 0.0238 (unpaired two-tailed t-test). d. Automated capillary western blot (WES) showing ASNS protein expression in leukemic cells isolated from mice in a treated with ASNase or vehicle. β-Actin serves as the loading control. Each lane is a biological replicate. e. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood. Mice received vehicle, ASNase (25 IU/mouse, single dose; n = 3), GCN2-IN-6 (3 mg/kg, oral dose every 3.5 days; n = 3), or the combination (n = 3). No significant differences were observed between treatment groups before treatment (day 0). At day 7, all treatment groups showed reduced leukemic burden compared with vehicle (*p = 0.0300 for ASNase, **p = 0.0017 for GCN2-IN-6, ***p = 0.0009 for the combination; one-way ANOVA with Dunnett’s multiple-comparison correction). Dots represent group means; error bars indicate SEM.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a. Relative viability of leukemic cells isolated from mice treated with a single intravenous dose of ASNase (100 IU/mouse) or vehicle (n = 3 mice per group). Cells were treated ex vivo with a two-fold serial dilution of ASNase (maximum concentration 2000 mIU/mL) for 72 h before viability was assessed using CellTiter-Glo. Concentrations were log-transformed. Each dot represents the mean of three biological replicates; error bars indicate SD. b. Relative ASNS mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. **p = 0.0038 (unpaired two-tailed t-test). c. Relative ATF4 mRNA expression in leukemic cells isolated from mice in (a) treated with ASNase or vehicle. Error bars indicate SEM. *p = 0.0238 (unpaired two-tailed t-test). d. Automated capillary western blot (WES) showing ASNS protein expression in leukemic cells isolated from mice in a treated with ASNase or vehicle. β-Actin serves as the loading control. Each lane is a biological replicate. e. Leukemic burden in T-ALL PDX1 mice, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood. Mice received vehicle, ASNase (25 IU/mouse, single dose; n = 3), GCN2-IN-6 (3 mg/kg, oral dose every 3.5 days; n = 3), or the combination (n = 3). No significant differences were observed between treatment groups before treatment (day 0). At day 7, all treatment groups showed reduced leukemic burden compared with vehicle (*p = 0.0300 for ASNase, **p = 0.0017 for GCN2-IN-6, ***p = 0.0009 for the combination; one-way ANOVA with Dunnett’s multiple-comparison correction). Dots represent group means; error bars indicate SEM.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques: Isolation, Ex Vivo, Serial Dilution, Concentration Assay, Transformation Assay, Expressing, Two Tailed Test, Automated, Western Blot, Control, Comparison

a-d. Leukemic burden, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood, in T-ALL PDX models 1–4 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. e-f. Leukemic burden, measured as the percentage of human CD19-positive (hCD19⁺) cells in peripheral blood, in B-ALL PDX models 1 and 2 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. g. Spleen weight of AML PDX-bearing mice treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Spleens were collected at the experimental endpoint. Statistical significance was determined using the Kruskal-Wallis test. **p = 0.0012. h. Leukemic burden, measured as the percentage of hCD45⁺ cells in peripheral blood, in the AML PDX model following treatment with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML) with time and treatment as fixed effects. *p = 0.0325. i. Relative tumor growth of an ovarian cancer cell line-derived xenograft (CDX) treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0008 j. Tumor volume of a neuroblastoma PDX treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 4 per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0002. k – n. Relative tumor growth of four TNBC PDX models treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 5 mice per group). Dots represent group means; error bars indicate SEM. Statistical analysis was performed using a linear mixed-effects model (REML). Significance is indicated in the figure.

Journal: bioRxiv

Article Title: PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES

doi: 10.64898/2026.11.02.763650

Figure Lengend Snippet: a-d. Leukemic burden, measured as the percentage of human CD45-positive (hCD45⁺) cells in peripheral blood, in T-ALL PDX models 1–4 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. e-f. Leukemic burden, measured as the percentage of human CD19-positive (hCD19⁺) cells in peripheral blood, in B-ALL PDX models 1 and 2 treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Treatment was discontinued once vehicle-treated mice reached the experimental endpoint, and the remaining mice were monitored for survival. Survival was analyzed using the Kaplan-Meier method with log-rank (Mantel-Cox) testing. Significance is indicated in the figure. g. Spleen weight of AML PDX-bearing mice treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Spleens were collected at the experimental endpoint. Statistical significance was determined using the Kruskal-Wallis test. **p = 0.0012. h. Leukemic burden, measured as the percentage of hCD45⁺ cells in peripheral blood, in the AML PDX model following treatment with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 7 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML) with time and treatment as fixed effects. *p = 0.0325. i. Relative tumor growth of an ovarian cancer cell line-derived xenograft (CDX) treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 6 mice per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0008 j. Tumor volume of a neuroblastoma PDX treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 4 per group). Statistical analysis was performed using a linear mixed-effects model (REML). ***p = 0.0002. k – n. Relative tumor growth of four TNBC PDX models treated with vehicle or GCN2-IN-6 (3 mg/kg, orally, twice weekly; n = 5 mice per group). Dots represent group means; error bars indicate SEM. Statistical analysis was performed using a linear mixed-effects model (REML). Significance is indicated in the figure.

Article Snippet: Red blood cells were lysed using ACK lysis buffer (Gibco, #A1049201) , and remaining cells were stained using antibodies against human CD45 (Miltenyi Biotech, #130-110-632) or human CD19 (#12-0199-42).

Techniques: Analysis, Derivative Assay, Xenograft Assay

In vivo immunomodulatory effects of different modified surfaces in a DM model. (A) Schematic representation of the animal modeling and experimental treatment workflow. (B, C) hematoxylin and eosin staining of the peri-implant tissues in the femurs of DM rats 1 week after implantation, accompanied by quantitative analysis of the fibrous capsule thickness (scale bar = 100 μm, n = 5). (D–G) Immunofluorescence staining evaluating the polarization state of macrophages surrounding the implants (green: macrophage marker cluster of differentiation (CD) 68; red: M1 marker CD86 and M2 marker CD206; blue: nuclei), along with corresponding quantitative analysis of the fluorescence signals (scale bar = 100 μm, n = 5). (H–K) Immunohistochemical staining assessing the expression of the pro-inflammatory marker tumor necrosis factor-α and the anti-inflammatory marker interleukin-10 in the peri-implant area, with quantitative results of the positive staining areas (scale bar = 100 μm, n = 5). Data are expressed as the mean ± standard deviation, with statistical analysis performed using one-way ANOVA and Tukey's post-hoc test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate statistical significance.

Journal: Bioactive Materials

Article Title: Integrated apoptotic extracellular vesicle-recruitment peptide coating reprograms the diabetic bone microenvironment and orchestrates enhanced implant osseointegration

doi: 10.1016/j.bioactmat.2026.05.059

Figure Lengend Snippet: In vivo immunomodulatory effects of different modified surfaces in a DM model. (A) Schematic representation of the animal modeling and experimental treatment workflow. (B, C) hematoxylin and eosin staining of the peri-implant tissues in the femurs of DM rats 1 week after implantation, accompanied by quantitative analysis of the fibrous capsule thickness (scale bar = 100 μm, n = 5). (D–G) Immunofluorescence staining evaluating the polarization state of macrophages surrounding the implants (green: macrophage marker cluster of differentiation (CD) 68; red: M1 marker CD86 and M2 marker CD206; blue: nuclei), along with corresponding quantitative analysis of the fluorescence signals (scale bar = 100 μm, n = 5). (H–K) Immunohistochemical staining assessing the expression of the pro-inflammatory marker tumor necrosis factor-α and the anti-inflammatory marker interleukin-10 in the peri-implant area, with quantitative results of the positive staining areas (scale bar = 100 μm, n = 5). Data are expressed as the mean ± standard deviation, with statistical analysis performed using one-way ANOVA and Tukey's post-hoc test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 indicate statistical significance.

Article Snippet: For IHC analysis, sections underwent heat-induced antigen retrieval and blocking prior to incubation with antibodies against TNF-α (GB11188, Servicebio, China), IL-10 (GB11534, Servicebio, China), and VEGF (GB15165, Servicebio, China) to identify differences in local inflammatory and angiogenic profiles.

Techniques: In Vivo, Modification, Staining, Immunofluorescence, Marker, Fluorescence, Immunohistochemical staining, Expressing, Standard Deviation